HHS Public Access

Author manuscript

Cancer Cell. Author manuscript; available in PMC 2021 March 16.

Published in final edited form as:

Cancer Cell. 2020 March 16; 37(3): 420. doi:10.1016/j.ccell.2020.03.003.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Jacqulyne P. Robichaux, **Yasir Y. Elamin**, **R.S.K. Vijayan**, **Monique B. Nilsson**, **Lemei Hu**, **Junqin He**, **Fahao Zhang**, **Marlese Pisegna**, **Alissa Poteete**, **Huiying Sun**, **Shuai Li**, **Ting Chen**, **Han Han**, **Marcelo Vailati Negrao**, **Jordi Rodon Ahnert**, **Lixia Diao**, **Jing Wang**, **Xiuning Le**, **Funda Meric-Bernstam**, **Mark Routbort**, **Brent Roeck**, **Zane Yang**, **Victoria M. Raymond**, **Richard B. Lanman**, **Garrett M. Frampton**, **Vincent A. Miller**, **Alexa B. Schrock**, **Lee A. Albacker**, **Kwok-kin Wong**, **Jason B. Cross**, **John V. Heymach**[*]

In Figure 3E of the original article, the authors showed a western blot of different Ba/F3 cell lines expressing various HER2 exon 20 mutations. It was recently brought to the authors' attention that there was an extra lane on the western blot and that the labels on the blot were unclearly labeled. The unintentional error was that the last lane of the western blot for HER2 (top row) contained a positive control cell line, H1781, with known expression of HER2 that was not cropped from the image, and the labels were shifted incorrectly. This error has now been corrected in the article online. While this correction does not affect the findings or the conclusions of the study, the authors would like to apologize for this error and any confusion that it may have caused for readers.

[*]**Correspondence**: jheymach@mdanderson.org.



Figure 3E.
The Most Common HER2 Variants in the Tyrosine Kinase Domain are Activating Mutations (Corrected)



Figure 3E.
The Most Common HER2 Variants in the Tyrosine Kinase Domain are Activating Mutations (Original)